MapLight Therapeutics (MPLT) Cash from Financing Activities (2024 - 2025)

MapLight Therapeutics' (MPLT) quarterly Cash from Financing Activities came in at $272.0 million in Q4 2025, up 5439200.0% year-on-year from N/an in Q4 2024, and up 5439200.0% quarter-over-quarter from $5000.0 in Q4 2024.

MapLight Therapeutics (MPLT) Cash from Financing Activities (2024 - 2025) Analysis & Trends

MapLight Therapeutics has disclosed Cash from Financing Activities across 2 years of filings, most recently posting $272.0 million for Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing Activities (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn - -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn - -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn - 7.00 Mn
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn -600,000.00
5 Evaxion A 1,334.43 Bn 1,334.42 Bn - -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn - 53,000.00
7 Psyence Biomedical 212.16 Bn 212.16 Bn - -
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn -538.80 Mn
9 Abivax 91.96 Bn 91.96 Bn - 85,464.43
10 MapLight Therapeutics 248.88 Mn 248.88 Mn - 271.97 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 271.97 Mn
Dec 31, 2025 271.97 Mn
Dec 31, 2024 5,000.00
Dec 31, 2024 5,000.00